Therefore, we select H1975 (EGFR L858R mutation and ErBb2 activation) and H1650 (EGFR Exon19 deletion and PTEN absence) to study the anti-cancer cell effects of BYL719 and gefitinib in the two NSCLC cell lines. Here, ERBB2 is linked to non-small cell lung carcinoma.